185 related articles for article (PubMed ID: 33244866)
21. From Janus kinase 2 to calreticulin: the clinically relevant genomic landscape of myeloproliferative neoplasms.
Cazzola M; Kralovics R
Blood; 2014 Jun; 123(24):3714-9. PubMed ID: 24786775
[TBL] [Abstract][Full Text] [Related]
22. Concomitant detection of BCR-ABL translocation and JAK2 V617F mutation in five patients with myeloproliferative neoplasm at diagnosis.
Cappetta M; Pérez V; Zubillaga MN; Elizondo V; Manrique G; Prosper I; Boschi S; Bonomi R; Pomoli S; Díaz L; Martínez L; Uriarte MR
Int J Lab Hematol; 2013 Feb; 35(1):e4-5. PubMed ID: 23062104
[No Abstract] [Full Text] [Related]
23. What is the role of JAK2(V617F) mutation in leukemic transformation of myeloproliferative neoplasms?
Lopes da Silva R; Ribeiro P; Lourenço A; Santos SC; Santos M; Costa I; de Sousa AB
Lab Hematol; 2011 Mar; 17(1):12-6. PubMed ID: 21421540
[TBL] [Abstract][Full Text] [Related]
24. Recent patents of gene mutation relative to JAK/STAT pathway and their implication in myeloproliferative diseases.
Shi Y; Xu C
Recent Pat DNA Gene Seq; 2008; 2(3):209-13. PubMed ID: 19075958
[TBL] [Abstract][Full Text] [Related]
25. JAK2: implications for diagnosis and classification of myeloproliferative disorders.
Campbell P
Lijec Vjesn; 2007 May; 129 Suppl 3():30-2. PubMed ID: 18959057
[No Abstract] [Full Text] [Related]
26. JAK2 V617F-mutated myeloproliferative neoplasia developing five years after wild-type JAK2 acute myeloid leukemia: a case report.
Girsberger S; Karow A; Lundberg P; Dirnhofer S; Lehmann T; Passweg JR; Tichelli A; Skoda R; Rovó A
Acta Haematol; 2013; 129(1):23-5. PubMed ID: 23006959
[No Abstract] [Full Text] [Related]
27. Simultaneous screening for JAK2 and calreticulin gene mutations in myeloproliferative neoplasms with high resolution melting.
Matsumoto N; Mori S; Hasegawa H; Sasaki D; Mori H; Tsuruda K; Imanishi D; Imaizumi Y; Hata T; Kaku N; Kosai K; Uno N; Miyazaki Y; Yanagihara K
Clin Chim Acta; 2016 Nov; 462():166-173. PubMed ID: 27693531
[TBL] [Abstract][Full Text] [Related]
28. CALR mutations in a cohort of JAK2 V617F negative patients with suspected myeloproliferative neoplasms.
Belcic Mikic T; Pajic T; Sever M
Sci Rep; 2019 Dec; 9(1):19838. PubMed ID: 31882869
[TBL] [Abstract][Full Text] [Related]
29. A novel JAK2 R564* variant in a patient with thrombocytosis.
Villanueva A; Poon KS; Gallardo CA; Chai CN; Chiu L; Yan B; Ding CSL; Yong KJ; Zhou J; Lee J; Tan K; Ong KH
Int J Lab Hematol; 2020 Apr; 42(2):e38-e41. PubMed ID: 31441587
[No Abstract] [Full Text] [Related]
30. The use of genetic tests to diagnose and manage patients with myeloproliferative and myeloproliferative/myelodysplastic neoplasms, and related disorders.
Cross NCP; Godfrey AL; Cargo C; Garg M; Mead AJ;
Br J Haematol; 2021 Nov; 195(3):338-351. PubMed ID: 34409596
[No Abstract] [Full Text] [Related]
31. The saga of JAK2 mutations and translocations in hematologic disorders: pathogenesis, diagnostic and therapeutic prospects, and revised World Health Organization diagnostic criteria for myeloproliferative neoplasms.
Smith CA; Fan G
Hum Pathol; 2008 Jun; 39(6):795-810. PubMed ID: 18538168
[TBL] [Abstract][Full Text] [Related]
32. Changing concepts of diagnostic criteria of myeloproliferative disorders and the molecular etiology and classification of myeloproliferative neoplasms: from Dameshek 1950 to Vainchenker 2005 and beyond.
Michiels JJ; Berneman Z; Schroyens W; De Raeve H
Acta Haematol; 2015; 133(1):36-51. PubMed ID: 25116092
[TBL] [Abstract][Full Text] [Related]
33. Extinction of myeloproliferative neoplasm by acquisition of a lymphoid disease: JAK2 (V617F) and JAK2 exon 12 allele burden disappearance during the follow-up of two patients.
Mahé K; Luque Paz D; Couturier MA; Chauveau A; Quintin-Roué I; Berthou C; Ugo V; Lippert E; Ianotto JC
Ann Hematol; 2016 Feb; 95(3):529-31. PubMed ID: 26611851
[No Abstract] [Full Text] [Related]
34. JAK2 mutations and clinical practice in myeloproliferative neoplasms.
Tefferi A
Cancer J; 2007; 13(6):366-71. PubMed ID: 18032973
[TBL] [Abstract][Full Text] [Related]
35. [JAK2 mutation and thrombosis - recommendations for screening].
Linnemann B; Lindhoff-Last E
Dtsch Med Wochenschr; 2011 Dec; 136(48):2454-7. PubMed ID: 22109574
[No Abstract] [Full Text] [Related]
36. Calreticulin gene mutations in myeloproliferative neoplasms without Janus kinase 2 mutations.
Sun C; Zhang S; Li J
Leuk Lymphoma; 2015 Jun; 56(6):1593-8. PubMed ID: 25115511
[TBL] [Abstract][Full Text] [Related]
37. Myeloproliferative neoplasms: JAK2 signaling pathway as a central target for therapy.
Pasquier F; Cabagnols X; Secardin L; Plo I; Vainchenker W
Clin Lymphoma Myeloma Leuk; 2014 Sep; 14 Suppl():S23-35. PubMed ID: 25486952
[TBL] [Abstract][Full Text] [Related]
38. Molecular testing for JAK2, MPL, and CALR in myeloproliferative neoplasms.
Xia D; Hasserjian RP
Am J Hematol; 2016 Dec; 91(12):1277-1280. PubMed ID: 27727468
[TBL] [Abstract][Full Text] [Related]
39. An update of molecular pathogenesis and diagnosis of myeloproliferative disorders in the JAK2 era.
Zhang SJ; Li JY
Chin Med J (Engl); 2008 Sep; 121(18):1838-42. PubMed ID: 19080367
[No Abstract] [Full Text] [Related]
40. Clonal architecture of JAK2V617F mutated cells during treatment with ruxolitinib.
Pacilli A; Fanelli T; Mannarelli C; Rotunno G; Pancrazzi A; Vannucchi AM; Guglielmelli P
Hematol Oncol; 2018 Feb; 36(1):357-359. PubMed ID: 28474777
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
